This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (54)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Gideon Koren, MD; Vera Rose, MD; Sasson Lavi, MD; Richard Rowe, MD

JAMA. 1985;254(6):767-769.

Abstract
The efficacy of high-dose salicylates in reducing the coronary artery involvement of Kawasaki disease was compared in 36 children who received acetylsalicylic acid, 80 to 180 mg/kg/day, and in 18 who did not receive high-dose salicylates during the febrile phase of the disease and whose fever was controlled mainly with acetaminophen. The two groups were comparable with respect to age and body weight. In the acetylsalicylic acid—treated group, the dose was adjusted to meet the therapeutic serum concentration range (20 mg/dL). There were significantly more cases of coronary involvement in the nontreated group (50%) than in the salicylate-treated group (16.6%) and of coronary aneurysms (39% vs 3%). During the febrile phase of the disease, salicylate serum concentrations achieved with a given dose were on the average twofold lower than during the nonfebrile phase, owing to impaired absorption of acetylsalicylic acid. It is suggested that despite the difficulty in achieving therapeutic serum concentrations of salicylate during the febrile phase of Kawasaki disease with a dose as high as 100 mg/kg/day, this dose is potentially capable of preventing the associated coronary disease.

(JAMA 1985;254:767-769)

Author Affiliations
From the Divisions of Clinical Pharmacology (Dr Koren), Cardiology (Drs Rose and Rowe), and Immunology and Rheumatology (Dr Lavi), Department of Pediatrics, and The Research Institute (Dr Koren), The Hospital for Sick Children, and the Departments of Pharmacology (Dr Koren) and Pediatrics (Drs Koren, Rose, Lavi, and Rowe), University of Toronto.

Footnotes
Reprint requests to Division of Clinical Pharmacology, The Hospital for Sick Children, 555 University Ave, Toronto, Ontario, Canada M5G 1x8 (Dr Koren).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Comparison of High-Dose and Low-Dose Aspirin Plus Intravenous Immunoglobulin in the Treatment of Kawasaki Syndrome
Saulsbury
CLIN PEDIATR 2002;41:597-601.
ABSTRACT  

Antithrombotic Therapy in Children
Monagle et al.
Chest 2001;119 :344S-370S.
FULL TEXT  

Adult Kawasaki Disease: Report of Two Cases Treated With Intravenous Gamma Globulin
Jackson et al.
Arch Intern Med 1994;154:1398-1405.
ABSTRACT  

The Perineal Eruption of Kawasaki Syndrome
Friter and Lucky
Arch Dermatol 1988;124:1805-1810.
ABSTRACT  

Kawasaki Disease and Perineal Rash
Urbach et al.
Arch Pediatr Adolesc Med 1988;142:1174-1176.
ABSTRACT  

Adult Kawasaki Syndrome
Butler et al.
Arch Dermatol 1987;123:1356-1361.
ABSTRACT  

Correlates of Coronary Artery Aneurysm Formation in Patients With Kawasaki Disease
Daniels et al.
Arch Pediatr Adolesc Med 1987;141:205-207.
ABSTRACT  

Kawasaki Disease and the Plight of the Platelet
CORRIGAN
Arch Pediatr Adolesc Med 1986;140:1223-1224.
ABSTRACT  

Preventing Coronary Involvement in Kawasaki Disease
Calabro et al.
JAMA 1986;255:200-200.
ABSTRACT  

Kawasaki Syndrome: Still a Mystery After 20 Years
Bell
JAMA 1985;254:801-802.
ABSTRACT